Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

Merck has had a successful track record of beating estimates, having surpassed EPS expectations 88% of the time and beating ...

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Earnings season begins this week. With the tariff overhang and higher expectations for coming quarters, forward earnings guidance from management will be crucial.

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 14 trades. If we ...

26 analysts have shared their evaluations of Regeneron Pharmaceuticals REGN during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...

Wall Street expects a year-over-year decline in earnings on higher revenues when United Airlines (UAL) reports results for the quarter ended June 2025. While this widely-known consensus outlook is ...

Pegasystems (PEGA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives ...

Bispecific antibodies are already available for treating multiple myeloma. FDA approval of Regeneron Pharmaceuticals’ new drug, Lynozyfic, comes with dosing flexibility that sets it apart from ...